Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SGLT2 inhibition improves sarcomere contractile dysfunction in human models of dilated cardiomyopathy.

Journal of translational medicine - 31 Jul 2026

Plota Daria, Saleem Hafiza Nosheen, Lin Kun-Han, Wali Ruheen, Cheruiyot Cleophas, Münzel Luca, Hutschenreiter Tabea, Tiburcy Malte, Meyer Tim, Habeck Michael, Wiedmann Felix, Schmidt Constanze, Zimmermann Wolfram-Hubertus, Ebert Antje

Abstract excerpt

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now widely applied in treatment plans for heart failure with reduced ejection fraction (HFrEF) patients, regardless of the presence of diabetes. SGLT2i, such as empagliflozin (EMP), reduce the risk of cardiovascular death and heart failure hospitalizations in HFrEF patients. However, the underlying molecular mechanisms of action, by which SGLT2i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Action Potentials
Share to Cardiomyopathy, Dilated

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Induced Pluripotent Stem Cells

Share to Mitochondria

Share to Myocardial Contraction

Share to Myocytes, Cardiac

Share to Sarcomeres

Share to Tropomyosin

Source

Open in PubMed Open full text

Identifiers

PMID: 42601625
DOI: 10.1186/s12967-026-08702-0
PMCID: PMC13474845

Genes

TPM1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SGLT2 inhibition improves sarcomere contractile dysfunction in human models of dilated cardiomyopathy.PMID 42601625Read ↗

Unveiling cellular mechanisms underlying MYZAP related dilated cardiomyopathy using patient specific hiPSC cardiomyocytes.Semantic proximity Read ↗

Evaluating and comparing the signalling and functional landscape of iPSC- CMs derived from patients with dilated cardiomyopathySemantic proximity Read ↗

Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated CardiomyopathySemantic proximity Read ↗

An Alternative Mechanism of Subcellular Iron Uptake Deficiency in Cardiomyocytes.Semantic proximity Read ↗

Mitigation of Stress-induced Structural Remodeling and Functional Deficiency in iPSC-CMs with PLN R9C Mutation by Promoting AutophagySemantic proximity Read ↗

Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.Semantic proximity Read ↗

Functional abnormalities in induced Pluripotent Stem Cell-derived cardiomyocytes generated from titin-mutated patients with dilated cardiomyopathySemantic proximity Read ↗

Direct Sarcomere Modulators Are Promising New Treatments for CardiomyopathiesSemantic proximity Read ↗

SGLT2 transcriptomic expression atlas supports a kidney-centric role for empagliflozin’s benefits in heart failureSemantic proximity Read ↗

Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes.Semantic proximity Read ↗

PGM1 deficiency disrupts sarcomere and mitochondrial function in a stem-cell cardiomyocyte modelSemantic proximity Read ↗

Disruption of cTnT-Mediated Sarcomere–Mitochondrial Communication Results in Dilated CardiomyopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.